Data from the Ph2 report-out last fall of KArXT in Schizophrenia was impressive.
1. Is anyone aware of efficacy data with any current approved therapeutic used to treat Schizophrenia that shows higher effect sizes than KRTX displayed at JPM '20 with the slide below?
2. Did you have concerns re: the AE profile despite the placebo-like results for the following:
• Weight gain
• Extrapyramidal symptoms/akathisia?
3. Somewhat of a catalyst drought ahead in 2020 for KRTX, but breakthrough therapy designation in Schizo from FDA would be a nice surprise. Do you think it's likely?